Beyond Air, INC 8-K filings

Beyond Air, Inc. has finalized a $11.5 million loan agreement, issuing warrants to purchase common stock to the lenders as part of the deal.

Beyond Air has announced its 2025 Annual Meeting of Stockholders will be held on December 9, 2024, and has set a deadline of October 19, 2024, for shareholder proposals and director nominations.

Beyond Air has entered into a binding term sheet for a $11.5 million secured loan with its CEO and a director, featuring a 15% interest rate and a royalty on net sales.

Beyond Air has announced a $20.6 million private placement offering, aimed at strengthening its balance sheet and extending its cash runway.

Beyond Air announced a 45% increase in quarterly revenue and the appointment of a new CEO for its NeuroNOS subsidiary, while also receiving a delisting notice from Nasdaq due to its stock price falling below $1.00.

Beyond Air amended its loan agreement, issued warrants to lenders, and provided a financial update including revised revenue guidance and a capital conservation strategy.

Beyond Air has appointed David Webster as Chief Commercial Officer, effective July 8, 2024, to lead the commercialization of their LungFit system.

Beyond Air, Inc. has announced a $16 million registered direct offering of common stock and warrants to institutional and accredited investors.

Beyond Air's stockholders approved an increase of 3,000,000 shares for its equity incentive plan and re-elected all seven board members at the 2024 Annual Meeting.

Beyond Air has amended its sales agreement to remove Oppenheimer & Co. as a sales agent for its at-the-market equity offering, leaving Truist Securities as the sole agent.

Beyond Air announced a significant 60% sequential revenue increase in Q3 FY2024, alongside advancements in their LungFit product line and cancer treatment programs.